Trial Profile
A phase I trial to Evaluate the Tolerability, Safety and Pharmacokinetics of RF-A089 in patients With Advanced ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs RF-A089 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Oct 2018 New trial record